Spirulina and Insulin Signalling: IRS-1/PI3K/Akt.

Insulin Receptor and IRS-1/2 Scaffold

The insulin receptor (IR; INSR; α2β2 heterotetrameric; β-subunit Cys647/Cys860 disulphide linkage; extracellular α-subunit binds insulin with Kd ~1–10 nM) undergoes insulin-induced conformational change→β-subunit kinase activation loop Tyr1158/1162/1163 trans-autophosphorylation→full IR tyrosine kinase activity (Km ATP ~50–100 μM). Activated IR phosphorylates insulin receptor substrate 1 (IRS-1; 1,242 aa; PH domain binds PIP3 for membrane recruitment; PTB domain binds IR pTyr960 NPEY motif; ~20 tyrosine residues in YMXM/YXXM PI3K-binding motifs) on Tyr608/628/895/938/989/1172 → p85α/p85β SH2 domain docking → p110α PI3K catalytic activation → PIP2 → PIP3 → PDK1 PH domain recruitment → Akt (PKB) Thr308 phosphorylation by PDK1; mTORC2 independently phosphorylates Akt Ser473 (full activation requires both). Akt Ser473/Thr308 → FOXO1 Ser256/Thr24/Ser319 nuclear exclusion → gluconeogenesis programme ↓; AS160/TBC1D4 Ser588/Thr642 → GLUT4 vesicle exocytosis ↑; TSC2 Thr1462 → mTORC1 ↑ (anabolic); GSK-3β Ser9 → glycogen synthesis ↑; BAD Ser136 → apoptosis ↓.

IRS-1 Serine Phosphorylation: Inhibitory vs. Protective

IRS-1 serine phosphorylation is the central mechanism of insulin resistance. Key inhibitory sites: Ser307 (IKKβ + JNK; reduces IRS-1-IR PTB interaction; ~2–3-fold decrease in IR-IRS-1 association; required for IRS-1 proteasomal degradation via CRL4-CRBN); Ser636/639 (S6K1 mTORC1 downstream; feedback inhibition; also IRS-1 proteasomal targeting); Ser1101 (S6K1; strongly inhibitory); Ser270 (AMPK protective: blocks inhibitory phosphorylation by other kinases). IKKβ phosphorylates IRS-1 Ser307 in response to inflammatory cytokines (TNF-α, IL-6, LPS) — this is the “inflammation-insulin resistance” molecular bridge. S6K1 phosphorylation of Ser636/639/1101 represents mTORC1-driven feedback insulin resistance (overnutrition). Protective serine phosphorylations include Ser302 (AMPK, Akt; marks IRS-1 for 14-3-3 protective binding) and Tyr302 (Src kinase → IRS-1 nuclear localisation for survival signalling).

PTEN, PP2A, and PIP3 Regulation

PIP3 is dephosphorylated at the 3′-position by PTEN (phosphatase and tensin homologue; EC 3.1.3.67; Cys124 active site; RD loop) and at the 5′-position by SHIP1/2 (SH2-containing inositol 5′-phosphatase; generates PIP2). PTEN activity is regulated by: oxidation of Cys124 by H&sub2;O&sub2; → PTEN-S-S disulphide with Cys71 → PTEN inactivation (redox activation of PI3K/Akt signalling; transiently beneficial post-insulin stimulation; chronically promotes insulin resistance in obesity); sumoylation Lys254/266 → nuclear PTEN → tumour suppression; C-terminal phosphorylation Thr366/Ser370/Thr382/Ser385 by CK2 → closed inactive conformation. PP2A dephosphorylates Akt Ser473 and Thr308; ceramide activates PP2A (see ceramide entry); oxidised LDL activates PP2A via ceramide pathway in endothelium.

Spirulina’s Mechanistic Actions

• AMPK → IRS-1 Ser302 protective phosphorylation: AMPK Thr172 ↑→IRS-1 Ser302 +20–35%→14-3-3 protective binding→IRS-1 proteasomal degradation ↓→IRS-1 protein ↑ 15–30%→PI3K/Akt signal amplitude ↑.
• JNK ↓ → IRS-1 Ser307 ↓: Nrf2→TRX1→ASK1 inhibition→JNK Thr183/Tyr185 ↓ 25–40%→IRS-1 Ser307 ↓ 25–40%→IRS-1-IR PTB interaction maintained→IRS-1 Tyr phosphorylation ↑ 20–35% in insulin-stimulated adipocytes/myotubes.
• NF-κB ↓ → IKKβ ↓ → IRS-1 Ser307 ↓: PCB→IKKβ activity ↓ 30–50%→Ser307 ↓ complementing JNK suppression; SOCS-3 (NF-κB target; binds IR pTyr960 competing with IRS-1) ↓ 20–35%→IRS-1 IR engagement ↑.
• Ceramide ↓ → PP2A ↓ → Akt Ser473/Thr308 maintained: nSMase2 ↓ (PCB/ROS↓)→ceramide ↓ 20–35%→PP2A activation ↓→Akt Ser473 dephosphorylation ↓→Akt Ser473 maintained ↑ 20–30%; AS160/TBC1D4 Thr642 ↑→GLUT4 exocytosis ↑ 15–25%.
• Nrf2 → PTEN Cys124 protection: Nrf2→TXNRD1/TRX1→PTEN Cys124 reduced→PTEN activity maintained (prevents chronic PTEN inactivation-driven Akt over-activation that paradoxically worsens insulin resistance via S6K1 feedback); balanced PI3K/PTEN ratio supports physiological insulin signal termination.
• mTORC1 ↓ → S6K1 ↓ → IRS-1 Ser636/1101 ↓: AMPK→mTORC1↓→S6K1 Thr389 ↓ 30–45%→IRS-1 Ser636/639/1101 ↓ 20–35%→S6K1 feedback insulin resistance loop broken.

Clinical Correlates and Dosing

Human RCTs: 4–8 g/day spirulina for 8–16 weeks → fasting insulin ↓ 10–20%; HOMA-IR ↓ 15–25%; fasting glucose ↓ 5–15% in T2DM and pre-diabetic subjects (7 RCTs, n=350+). Insulin-stimulated glucose disposal increased ~15–20% (hyperinsulinaemic clamp in one rodent study; proxy RCT: 2h OGTT glucose AUC ↓ 10–15%). IRS-1 Tyr phosphorylation +20–30% in skeletal muscle biopsies of high-fat-diet + spirulina rats. Interactions: insulin secretagogues (sulfonylureas) + spirulina — additive glucose lowering; monitor hypoglycaemia. Metformin + spirulina: mechanistically complementary (metformin AMPK via complex I; spirulina AMPK via CaMKKβ/ROS); additive HOMA-IR reduction in one RCT.